Yu Xia

发表

JQ1, a bromodomain inhibitor, suppresses Th17 effectors by blocking p300‐mediated acetylation of RORγt

Cui-ping Ren, B. Li, Dandan Ren, 2020, British journal of pharmacology.

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers

Hong Wang, K. Kwek, J. Coward, 2022, Cancer Immunology, Immunotherapy.

Wiskott-Aldrich syndrome protein may be critical for CD8+ T cell function following MCMV infection.

Zaili Zhang, Juan Du, Lin Liu, 2019, Cellular immunology.

b-Glucan , a “ Specific ” Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 ( CD 11 b / CD 18 ) 1

T. Mayadas, V. Vetvicka, A. Coxon, 1999 .

Role of the Pumilio gene in the reproductive system of Schistosoma japonicum

Cui-ping Ren, W. Shao, Ji-jia Shen, 2020, Parasitology Research.

Therapeutic intervention with complement and β-glucan in cancer

V. Vetvicka, Jun Yan, G. D. Ross, 1999 .

Roles of Integrins CR3 and CR4 in Disease and Therapeutic Strategies

G. D. Ross, Yu Xia, 2000 .

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

T. Qu, T. Zhong, Baiyong Li, 2022, Journal for immunotherapy of cancer.

Glucan-Binding Lectin Site of CR 3 β CD 11 b Expressing the Functional Generation of Recombinant Fragments of

G. D. Ross, Yu Xia, 1999 .

The b-Glucan-Binding Lectin Site of Mouse CR 3 ( CD 11 b / CD 18 ) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC 3 b-Opsonized Target Cells 1

T. Mayadas, V. Vetvicka, Jun Yan, 1999 .

Response to iC 3 b-Opsonized Target Cells That Mediates Cytotoxic Activation in Generating a Primed State of the Receptor CR 3 ( CD 11 b / CD 18 ) and Its Function in-Glucan-Binding Lectin Site of Mouse β The

T. Mayadas, V. Vetvicka, Jun Yan, 1999 .

Function of the Lectin Domain of Mac-1/Complement Receptor Type 3 (CD11b/CD18) in Regulating Neutrophil Adhesion1

H. Petty, G. D. Ross, I. Mizukami, 2002, The Journal of Immunology.

Adhesion(CD11b/CD18) in Regulating Neutrophil Mac-1/Complement Receptor Type 3 Function of the Lectin Domain of

H. Petty, G. D. Ross, I. Mizukami, 2002 .

LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-κB/p50 and SLUG.

Hui-Bin Liu, Yu Xia, Yan Pu, 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.

A. Nagrial, K. Kwek, H. Gan, 2021 .

Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study

Wenhui Zhang, Min Zhang, Hongzhong Jin, 2022, Dermatology and Therapy.

Role of the Pumilio gene in the reproductive system of Schistosoma japonicum

Cui-ping Ren, Ji-jia Shen, Miao Liu, 2020, Parasitology Research.

430 A phase 1b/II clinical study of AK112, a PD-1/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer

R. An, Xiaoping Jin, Lingying Wu, 2021, Journal for ImmunoTherapy of Cancer.

436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy

Xiaozhong Chen, H. Mai, Shaojun Lin, 2021, Journal for ImmunoTherapy of Cancer.

MicroRNA-196a Overexpression Inhibits Apoptosis in Hemin-Induced K562 Cells.

Xingyun Zhao, Liang Yong, Ji-jia Shen, 2020, DNA and cell biology.

384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas

A. Nagrial, K. Kwek, H. Gan, 2020 .

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

N. Xu, G. Lou, Qi Zhou, 2022, Gynecologic Oncology.

A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).

H. Cai, Xin Huang, Baiyong Li, 2022, Journal of Clinical Oncology.

702 Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy

N. Chen, Xiaoping Jin, T. Zhong, 2020 .

Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.

G. Shao, S. Jiao, Xiaoping Jin, 2021 .

Construction of a human monoclonal antibody against bFGF for suppression of NSCLC

Meng Xu, Yu Zhang, Baiyong Li, 2018, Journal of Cancer.

Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC).

Liangfang Shen, Jiahong Dong, Jia Fan, 2020 .

A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.

Yanqiu Zhao, Li Zhang, Lin Wang, 2022, Journal of Clinical Oncology.

A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC).

Yuanrong Dai, S. Ren, Caicun Zhou, 2022, Journal of Clinical Oncology.

Therapeutic intervention with complement and complement receptors in cancer

T. Mayadas, V. Vetvicka, Jun Yan, 1998 .

A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).

N. Yang, Yu-xiang Ma, Yun Fan, 2023, Lung cancer.

A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.

L. Shen, J. Ji, N. Yang, 2022, Journal of Clinical Oncology.

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.

Baiyong Li, Lin Wu, Bolin Chen, 2023, British journal of cancer.